XML 75 R54.htm IDEA: XBRL DOCUMENT
v3.20.4

Acquisitions and Other Strategic Transactions - Narrative (Details) € in Millions |  |  |  |  |  |  |  |  |  |  |  |  | 3 Months Ended | 12 Months Ended | 24 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 06, 2020 USD ($) | Oct. 11, 2019 USD ($) shares | Aug. 01, 2019 USD ($) | Jun. 14, 2019 USD ($) | Mar. 28, 2019 USD ($) | Dec. 14, 2018 USD ($) | Nov. 13, 2018 USD ($) | Jul. 31, 2018 USD ($) shares | May 23, 2018 USD ($) | May 18, 2018 USD ($) | Apr. 06, 2018 USD ($) | Feb. 14, 2018 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) shares | Dec. 31, 2020 EUR (€)
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent liability |  |  |  |  |  |  |  |  |  |  |  |  | $ 48,088,000 | $ 36,917,000 | $ 48,088,000 |  |  |
Payments to acquire intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,288,000 | 3,324,000 | $ 3,012,000 |  |
Impairment charges |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 36,504,000 | 23,750,000 | 657,000 |  |
QX Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire intangible assets |  |  |  |  |  |  |  |  |  | $ 750,000 |  |  |  |  |  |  |  |
NinePoint Medical, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan from acquisition |  |  |  |  |  |  |  |  |  |  | $ 10,500,000 |  |  |  |  |  |  |
Interest rate on loan |  |  |  |  |  |  |  |  |  |  | 9.00% |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |
Option to purchase outstanding equity, up to |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,900,000 | 3,000,000.0 |  |
Impairment charges |  |  |  |  |  |  |  |  |  |  |  |  | 20,500,000 |  | 20,500,000 |  |  |
Write off of accrued interest |  |  |  |  |  |  |  |  |  |  |  |  | $ (1,600,000) |  | (1,600,000) |  |  |
Distribution agreements | QX Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |
Fluidx |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  | 11.60% |  |  |  | 11.60%
Payments to acquire shares |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Cagent Vascular, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  | 19.50% |  |  |  | 19.50%
Payments to acquire shares |  |  |  |  |  |  |  | $ 2,200,000 |  |  |  |  |  |  |  |  | $ 3,000,000.0 |
Preferred limited liability company units (in units) | shares |  |  |  |  |  |  |  | 1,786,000 |  |  |  |  |  |  |  |  | 3,000,000 |
Fusion Medical, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  |  |  |  |  |  |  | 19.50% |  |  |  | 19.50%
KA Medical |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase consideration, upfront payment | $ 10,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase consideration, note payable | $ 4,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of note payable | 12 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
KA Medical | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life | 17 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Selio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  | 19.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investment |  | $ 2,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan from acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000 |  |  |  |
Interest rate on loan |  |  |  |  |  |  |  |  |  |  |  |  |  | 5.00% |  |  |  | 5.00%
Selio | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan commitment from acquisition | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 2
Selio | Ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares acquired (in shares) | shares |  | 3,900 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of option to purchase equity |  | 45 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Selio | C Ordinary shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares acquired (in shares) | shares |  | 1,365 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fibrovein Holdings Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase consideration, upfront payment |  |  | $ 13,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  | 12 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent liability |  |  | $ 934,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fibrovein Holdings Limited | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  | 12 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fibrovein Holdings Limited | STD Pharmaceutical Products Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brightwater |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase consideration, upfront payment |  |  |  | $ 35,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  | 12 years 10 months 24 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brightwater | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  | 13 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brightwater | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brightwater | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brightwater | Maximum | Achievement of CE Certification |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Earn-out payments |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brightwater | Maximum | Achievement of Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Earn-out payments |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vascular Insights |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase consideration, upfront payment |  |  |  |  |  | $ 40,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  | 11 years 9 months 18 days |  |  |  |  |  |  |  |  |  |  |  |
Contingent liability |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,500,000 | 7,500,000 |  |  |
Vascular Insights | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  | 12 years |  |  |  |  |  |  |  |  |  |  |  |
Vascular Insights | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  | 9 years |  |  |  |  |  |  |  |  |  |  |  |
Vascular Insights | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  | 8 years |  |  |  |  |  |  |  |  |  |  |  |
Cianna Medical |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase consideration, upfront payment |  |  |  |  |  |  | $ 135,000,000 |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  | 10 years 8 months 12 days |  |  |  |  |  |  |  |  |  |  |
Working capital adjustment |  |  |  |  |  |  | $ 1,200,000 |  |  |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  | 45,300,000 | 49,500,000 | 6,300,000 |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,500,000 |  |
Cianna Medical | Achievement of Supply Chain and Scalability Metrics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Earn-out payments |  |  |  |  |  |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |
Cianna Medical | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  | 11 years |  |  |  |  |  |  |  |  |  |  |
Cianna Medical | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |
Cianna Medical | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  | 8 years |  |  |  |  |  |  |  |  |  |  |
Cianna Medical | Maximum | Achievement of Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Earn-out payments |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  | 9 years 10 months 24 days |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  | $ 7,300,000 |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |
Becton, Dickinson and Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  | 8 years |  |  |  |  |  |
Contingent liability |  |  |  |  |  |  |  |  |  |  |  | $ 1,600,000 |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  |  |  |  | $ 100,300,000 |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 42,600,000 | $ 46,800,000 | 42,100,000 |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,800,000 |  |
Becton, Dickinson and Company | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  | 8 years |  |  |  |  |  |
Becton, Dickinson and Company | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  | 9 years |  |  |  |  |  |
Becton, Dickinson and Company | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  | 7 years |  |  |  |  |  |

X
- Definition Term of note payable issued as consideration of business combination. + References No definition available. + Details
Name: | mmsi_BusinessAcquisitionConsiderationTransferredTermOfNotePayable
Namespace Prefix: | mmsi_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Acquisition, Option To Acquire Percentage of Voting Interests + References No definition available. + Details
Name: | mmsi_BusinessAcquisitionOptionToAcquirePercentageofVotingInterests
Namespace Prefix: | mmsi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of note payable issued by acquirer in consideration for the business combination. + References No definition available. + Details
Name: | mmsi_BusinessCombinationConsiderationTransferredNotePayable
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Combination, Initial Working Capital Adjustment + References No definition available. + Details
Name: | mmsi_BusinessCombinationInitialWorkingCapitalAdjustment
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity Method Investment, Limited Liability Company (LLC) Units + References No definition available. + Details
Name: | mmsi_EquityMethodInvestmentLimitedLiabilityCompanyLLCUnits
Namespace Prefix: | mmsi_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loan commitment amount to parties associated with the reporting entity. + References No definition available. + Details
Name: | mmsi_LoanCommitmentRelatedParties
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Notes Receivable, Interest Rate, Stated Percentage + References No definition available. + Details
Name: | mmsi_NotesReceivableInterestRateStatedPercentage
Namespace Prefix: | mmsi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The period within which the option to purchase ordinary shares commences from the date of approval of product. + References No definition available. + Details
Name: | mmsi_TermOfOptionToPurchaseEquityFromReceivalOfApprovalOfProduct
Namespace Prefix: | mmsi_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The increase (decrease) during the reporting period in the amount due from borrowers for interest payments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(2)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(11)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_NotesReceivableRelatedPartiesNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mmsi_QXMedicalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mmsi_NinePointMedicalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mmsi_FluidxMedicalTechnologyLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mmsi_CagentVascularLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mmsi_FusionMedicalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_KaMedicalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_SelioMedicalLimitedSelioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=mmsi_OrdinarySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=mmsi_COrdinarySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_FibroveinHoldingsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=mmsi_STDPharmaceuticalProductsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_BrightwaterMedicalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=mmsi_AchievementOfCECertificationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=mmsi_AchievementOfSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_VascularInsightsLLCandVIManagementInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_CiannaMedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=mmsi_AchievementofSupplyChainandScalabilityMetricsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_DirectACCESSMedicalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_BectonDickinsonandCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |